CD8A and neoplasm: Early evidence by Zitvogel et al. first demonstrated that DEX bearing TAA‐loaded MHC class I complexes could elicit intense CD8+ T cell responses and confer tumor protection in immunocompetent mice.[65] Notably, these responses were absent in immune‐deficient models, highlighting the requirement for a functional adaptive immune compartment.